{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:39:12Z","timestamp":1791473952198,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12185-025-03951-z","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T17:02:09Z","timestamp":1740589329000},"page":"820-832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients"],"prefix":"10.1007","volume":"121","author":[{"given":"Yasutaka","family":"Masuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Sadato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7436-972X","authenticated-orcid":false,"given":"Takashi","family":"Toya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzuru","family":"Hosoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuko","family":"Hirama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"3951_CR1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-biochem-060815-014710","volume":"85","author":"AC Joerger","year":"2016","unstructured":"Joerger AC, Fersht AR. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu Rev Biochem. 2016;85:375\u2013404. https:\/\/doi.org\/10.1146\/annurev-biochem-060815-014710.","journal-title":"Annu Rev Biochem"},{"issue":"22","key":"3951_CR2","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1301689.","journal-title":"N Engl J Med"},{"issue":"23","key":"3951_CR3","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1516192.","journal-title":"N Engl J Med"},{"key":"3951_CR4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-518886","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013. https:\/\/doi.org\/10.1182\/blood-2013-08-518886.","journal-title":"Blood"},{"issue":"5","key":"3951_CR5","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","volume":"128","author":"KH Metzeler","year":"2016","unstructured":"Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, G\u00f6rlich D, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128(5):686\u201398. https:\/\/doi.org\/10.1182\/blood-2016-01-693879.","journal-title":"Blood"},{"issue":"10","key":"3951_CR6","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26(10):1549\u201356. https:\/\/doi.org\/10.1038\/s41591-020-1008-z.","journal-title":"Nat Med"},{"issue":"7","key":"3951_CR7","doi-asserted-by":"publisher","first-page":"E232","DOI":"10.1002\/ajh.26546","volume":"97","author":"T Badar","year":"2022","unstructured":"Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, et al. Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. Am J Hematol. 2022;97(7):E232\u20135. https:\/\/doi.org\/10.1002\/ajh.26546.","journal-title":"Am J Hematol"},{"issue":"9","key":"3951_CR8","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","volume":"119","author":"FG R\u00fccker","year":"2012","unstructured":"R\u00fccker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119(9):2114\u201321. https:\/\/doi.org\/10.1182\/blood-2011-08-375758.","journal-title":"Blood"},{"issue":"7","key":"3951_CR9","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","volume":"33","author":"D Haase","year":"2019","unstructured":"Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019;33(7):1747\u201358. https:\/\/doi.org\/10.1038\/s41375-018-0351-2.","journal-title":"Leukemia"},{"issue":"1","key":"3951_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/leu.2008.173","volume":"23","author":"D Bowen","year":"2009","unstructured":"Bowen D, Groves MJ, Burnett AK, Patel Y, Allen C, Green C, et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia. 2009;23(1):203\u20136. https:\/\/doi.org\/10.1038\/leu.2008.173.","journal-title":"Leukemia"},{"issue":"3","key":"3951_CR11","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/leu.2015.304","volume":"30","author":"DA Sallman","year":"2016","unstructured":"Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016;30(3):666\u201373. https:\/\/doi.org\/10.1038\/leu.2015.304.","journal-title":"Leukemia"},{"issue":"1","key":"3951_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood.2021013983","volume":"140","author":"M Tashakori","year":"2022","unstructured":"Tashakori M, Kadia T, Loghavi S, Daver N, Kanagal-Shamanna R, Pierce S, et al. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022;140(1):58\u201372. https:\/\/doi.org\/10.1182\/blood.2021013983.","journal-title":"Blood"},{"issue":"3","key":"3951_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/bloodadvances.2023010417","volume":"8","author":"MT Nawas","year":"2024","unstructured":"Nawas MT, Kosuri S. Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS\/AML. Blood Adv. 2024;8(3):553\u201361. https:\/\/doi.org\/10.1182\/bloodadvances.2023010417.","journal-title":"Blood Adv"},{"issue":"28","key":"3951_CR14","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1200\/jco.23.00866","volume":"41","author":"J Versluis","year":"2023","unstructured":"Versluis J, Saber W, Tsai HK, Gibson CJ, Dillon LW, Mishra A, et al. Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the blood and marrow transplant clinical trials network 1102 study. J Clin Oncol. 2023;41(28):4497\u2013510. https:\/\/doi.org\/10.1200\/jco.23.00866.","journal-title":"J Clin Oncol"},{"issue":"15","key":"3951_CR15","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood.2021014472","volume":"139","author":"T Grob","year":"2022","unstructured":"Grob T, Al Hinai ASA, Sanders MA, Kavelaars FG, Rijken M, Gradowska PL, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022;139(15):2347\u201354. https:\/\/doi.org\/10.1182\/blood.2021014472.","journal-title":"Blood"},{"issue":"6","key":"3951_CR16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/bjh.13912","volume":"172","author":"JM Middeke","year":"2016","unstructured":"Middeke JM, Herold S, R\u00fccker-Braun E, Berdel WE, Stelljes M, Kaufmann M, et al. TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2016;172(6):914\u201322. https:\/\/doi.org\/10.1111\/bjh.13912.","journal-title":"Br J Haematol"},{"issue":"22","key":"3951_CR17","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","volume":"4","author":"NJ Short","year":"2020","unstructured":"Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020;4(22):5681\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2020003120.","journal-title":"Blood Adv"},{"issue":"4","key":"3951_CR18","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1182\/bloodadvances.2020003508","volume":"5","author":"AM Hunter","year":"2021","unstructured":"Hunter AM, Komrokji RS, Yun S, Al Ali N, Chan O, Song J, et al. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021;5(4):1017\u201328. https:\/\/doi.org\/10.1182\/bloodadvances.2020003508.","journal-title":"Blood Adv"},{"issue":"14","key":"3951_CR19","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1080\/10428194.2021.1957869","volume":"62","author":"SA Patel","year":"2021","unstructured":"Patel SA, Lloyd MR, Cerny J, Shi Q, Simin K, Ediriwickrema A, et al. Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia. Leuk Lymphoma. 2021;62(14):3348\u201360. https:\/\/doi.org\/10.1080\/10428194.2021.1957869.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"3951_CR20","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1080\/10428194.2020.1759051","volume":"61","author":"JP Bewersdorf","year":"2020","unstructured":"Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, et al. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience. Leuk Lymphoma. 2020;61(9):2180\u201390. https:\/\/doi.org\/10.1080\/10428194.2020.1759051.","journal-title":"Leuk Lymphoma"},{"key":"3951_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123210","author":"D Zhao","year":"2023","unstructured":"Zhao D, Zarif M, Zhou Q, Capo-Chichi JM, Schuh A, Minden MD, et al. TP53 mutations in AML patients are associated with dismal clinical outcome irrespective of frontline induction regimen and allogeneic hematopoietic cell transplantation. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15123210.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"3951_CR22","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912\u20139. https:\/\/doi.org\/10.1182\/blood-2005-05-2004.","journal-title":"Blood"},{"issue":"12","key":"3951_CR23","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628\u201333. https:\/\/doi.org\/10.1016\/j.bbmt.2009.07.004.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3951_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.12.497","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009. https:\/\/doi.org\/10.1016\/j.bbmt.2008.12.497.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"3951_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419\u201325.","journal-title":"Blood"},{"issue":"29","key":"3951_CR26","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1200\/jco.2008.16.0259","volume":"26","author":"DA Breems","year":"2008","unstructured":"Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791\u20137. https:\/\/doi.org\/10.1200\/jco.2008.16.0259.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3951_CR27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41409-020-01016-9","volume":"56","author":"Y Najima","year":"2021","unstructured":"Najima Y, Sadato D, Harada Y, Oboki K, Hirama C, Toya T, et al. Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT. Bone Marrow Transplant. 2021;56(2):334\u201346. https:\/\/doi.org\/10.1038\/s41409-020-01016-9.","journal-title":"Bone Marrow Transplant"},{"key":"3951_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255257","author":"D Sadato","year":"2021","unstructured":"Sadato D, Hirama C, Kaiho-Soma A, Yamaguchi A, Kogure H, Takakuwa S, et al. Archival bone marrow smears are useful in targeted next-generation sequencing for diagnosing myeloid neoplasms. PLoS ONE. 2021. https:\/\/doi.org\/10.1371\/journal.pone.0255257.","journal-title":"PLoS ONE"},{"issue":"11","key":"3951_CR29","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.3324\/haematol.2023.284953","volume":"109","author":"K Yoshifuji","year":"2024","unstructured":"Yoshifuji K, Sadato D, Toya T, Motomura Y, Hirama C, Takase H, et al. Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma. Haematologica. 2024;109(11):3641\u20139. https:\/\/doi.org\/10.3324\/haematol.2023.284953.","journal-title":"Haematologica"},{"key":"3951_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010004","author":"S Yamamoto","year":"2018","unstructured":"Yamamoto S, Iwakuma T. Regulators of oncogenic mutant TP53 gain of function. Cancers (Basel). 2018. https:\/\/doi.org\/10.3390\/cancers11010004.","journal-title":"Cancers (Basel)."},{"key":"3951_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.607670","volume":"8","author":"E Alvarado-Ortiz","year":"2020","unstructured":"Alvarado-Ortiz E, de la Cruz-L\u00f3pez KG, Becerril-Rico J, Sarabia-S\u00e1nchez MA, Ortiz-S\u00e1nchez E, Garc\u00eda-Carranc\u00e1 A. Mutant p53 gain-of-function: role in cancer development, progression, and therapeutic approaches. Front Cell Dev Biol. 2020;8: 607670. https:\/\/doi.org\/10.3389\/fcell.2020.607670.","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"3951_CR32","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454\u201365. https:\/\/doi.org\/10.1182\/blood-2012-03-420489.","journal-title":"Blood"},{"key":"3951_CR33","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200008","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022. https:\/\/doi.org\/10.1056\/EVIDoa2200008.","journal-title":"NEJM Evid."},{"issue":"14","key":"3951_CR34","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1200\/jco.20.02342","volume":"39","author":"T Cluzeau","year":"2021","unstructured":"Cluzeau T, Sebert M, Rahm\u00e9 R, Cuzzubbo S, Lehmann-Che J, Madelaine I, et al. Eprenetapopt plus azacitidine in tp53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase ii study by the groupe francophone des my\u00e9lodysplasies (GFM). J Clin Oncol. 2021;39(14):1575\u201383. https:\/\/doi.org\/10.1200\/jco.20.02342.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3951_CR35","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/bjh.13248","volume":"169","author":"G Oshikawa","year":"2015","unstructured":"Oshikawa G, Kakihana K, Saito M, Aoki J, Najima Y, Kobayashi T, et al. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia. Br J Haematol. 2015;169(5):756\u20139. https:\/\/doi.org\/10.1111\/bjh.13248.","journal-title":"Br J Haematol"},{"issue":"8","key":"3951_CR36","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/s41409-024-02311-5","volume":"59","author":"S Kaito","year":"2024","unstructured":"Kaito S, Najima Y, Sadato D, Hirama C, Kishida Y, Nagata A, et al. Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies. Bone Marrow Transplant. 2024;59(8):1169\u201375. https:\/\/doi.org\/10.1038\/s41409-024-02311-5.","journal-title":"Bone Marrow Transplant"},{"key":"3951_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.09.004","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005. https:\/\/doi.org\/10.1016\/j.bbmt.2005.09.004.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"3951_CR38","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1002\/cncr.34268","volume":"128","author":"J Loke","year":"2022","unstructured":"Loke J, Labopin M, Craddock C, Cornelissen JJ, Labussi\u00e8re-Wallet H, Wagner-Drouet EM, et al. Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. Cancer. 2022;128(15):2922\u201331. https:\/\/doi.org\/10.1002\/cncr.34268.","journal-title":"Cancer"},{"issue":"6","key":"3951_CR39","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1056\/NEJMoa1611604","volume":"376","author":"RC Lindsley","year":"2017","unstructured":"Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376(6):536\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1611604.","journal-title":"N Engl J Med"},{"issue":"22","key":"3951_CR40","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1002\/cncr.30203","volume":"122","author":"TM Kadia","year":"2016","unstructured":"Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, et al. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016;122(22):3484\u201391. https:\/\/doi.org\/10.1002\/cncr.30203.","journal-title":"Cancer"},{"issue":"18","key":"3951_CR41","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1182\/bloodadvances.2023010312","volume":"7","author":"A Stengel","year":"2023","unstructured":"Stengel A, Meggendorfer M, Walter W, Baer C, Nadarajah N, Hutter S, et al. Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS. Blood Adv. 2023;7(18):5540\u20138.","journal-title":"Blood Adv"},{"key":"3951_CR42","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1182\/blood-2021-154151","volume":"138","author":"MT Byrne","year":"2021","unstructured":"Byrne MT, Kurian TJ, Patel DA, Tamari R, Hong S, Abdelhakim H, et al. Non-relapse mortality in TP53-mutated MDS\/AML-a multi-center collaborative study. Blood. 2021;138:2922.","journal-title":"Blood"},{"issue":"3","key":"3951_CR43","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41375-020-0932-8","volume":"35","author":"M Cerrano","year":"2021","unstructured":"Cerrano M, Duchmann M, Kim R, Vasseur L, Hirsch P, Thomas X, et al. Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy. Leukemia. 2021;35(3):712\u201323. https:\/\/doi.org\/10.1038\/s41375-020-0932-8.","journal-title":"Leukemia"},{"issue":"34","key":"3951_CR44","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1200\/jco.22.00181","volume":"40","author":"A Mishra","year":"2022","unstructured":"Mishra A, Tamari R, DeZern AE, Byrne MT, Gooptu M, Chen YB, et al. Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2022;40(34):3985\u201393. https:\/\/doi.org\/10.1200\/jco.22.00181.","journal-title":"J Clin Oncol"},{"key":"3951_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the world health organization classification of haematolymphoid tumours myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022. https:\/\/doi.org\/10.1038\/s41375-022-01613-1.","journal-title":"Leukemia"},{"issue":"11","key":"3951_CR46","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328. https:\/\/doi.org\/10.1182\/blood.2022015850.","journal-title":"Blood"},{"issue":"9","key":"3951_CR47","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","volume":"6","author":"OK Weinberg","year":"2022","unstructured":"Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber DA, Dal Cin P, et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML. Blood Adv. 2022;6(9):2847\u201353. https:\/\/doi.org\/10.1182\/bloodadvances.2021006239.","journal-title":"Blood Adv"},{"issue":"16","key":"3951_CR48","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1182\/bloodadvances.2023010156","volume":"7","author":"HJ Abel","year":"2023","unstructured":"Abel HJ, Oetjen KA, Miller CA, Ramakrishnan SM, Day RB, Helton NM, et al. Genomic landscape of TP53-mutated myeloid malignancies. Blood Adv. 2023;7(16):4586\u201398. https:\/\/doi.org\/10.1182\/bloodadvances.2023010156.","journal-title":"Blood Adv"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03951-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03951-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03951-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:32:32Z","timestamp":1748259152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03951-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3951"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03951-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.N. received consulting fees from Astellas Pharma and Daiichi-Sankyo, and lecture fees from AbbVie, Astellas, Chugai Pharmaceutical, Daiichi Sankyo, JCR Pharma, MSD, Novartis Pharma, Sumitomo Pharma, Amgen, Bristol-Myers Squibb, CSL Behring, Janssen Pharmaceutical, Kyowa Kirin, Nippon Shinyaku, Otsuka Pharmaceutical, Takeda Pharmaceutical, and Meiji Seika Pharma. H.H. received lecture fees from Bristol-Myers Squibb and advisory fees from Novartis Pharma. N.D. received grants from Japan Agency for Medical Research and Development (24ek0510039h0003) and Japan Society for the Promotion of Science (23K06709), consulting fees from Janssen Pharmaceutical, and lecture fees from Nippon Shinyaku, Novartis Pharma, Daiichi-Sankyo, AstraZeneca, Otsuka Pharmaceutical, Asahi Kasei Pharma, Sanofi, Pfizer, Janssen Pharmaceutical, Kyowa Kirin, AbbVie, Astellas Pharma, Chugai Pharmaceutical, Shionogi & Co, Merck & Co, and Takeda Pharmaceutical. None of these are related to the current study. Other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and approved by the ethics committee of Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital (approval number 2203). Written informed consent was obtained from the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}